NCT04206618

Circulating Myokine Levels and Bone Metabolism

The Role of Myokines in Postmenopausal Osteoporosis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 220 (actual)
• Sponsor: 424 General Military Hospital · Academic / Other
• Sex: Female
• Age: 20 Years – 85 Years
• Healthy volunteers: Accepted

Summary

Circulating levels of several myokines will be measured in serum samples obtained from women in various categories of bone density and according to the presence of fracture or not as well as before and after treatment with teriparatide and denosumab

Detailed description

Serum samples for the measurement of several myokines will be obtained from: 1) equal groups of premenopausal women with normal BMD, postmenopausal women with normal BMD, postmenopausal women with osteopenia, and postmenopausal women with osteoporosis; 2) women with hip fracture compared with controls (women subjected to surgery due to knee osteoathritis); 3) women with osteoporosis treated with teriparatide or denosumab for 12 months

Conditions

• Osteoporosis, Postmenopausal

Interventions

Type	Name	Description
DRUG	Teriparatide	1 subcutaneous injection daily for 12 months
DRUG	Denosumab	1 subcutaneous injection every 6 months for 12 months

Timeline

• Start date: 2019-06-01
• Primary completion: 2020-09-30
• Completion: 2020-11-10
• First posted: 2019-12-20
• Last updated: 2021-01-12

Locations

1 site across 1 country: Greece

Regulatory

• FDA-regulated drug study